^
4d
Preliminary Exploratory Clinical Study of TC-D101 in the Treatment of DLL3-Positive Relapsed/Refractory Primary Small-Cell Lung Cancer (ChiCTR2500112639)
P=N/A, N=8, Not yet recruiting, Eastern Theater Command General Hospital of the Chinese People's Liberation Army (Jinling Hospital, Affiliated to Nanjing University Medical School);
New trial
|
DLL3 (Delta Like Canonical Notch Ligand 3)
4d
New trial
|
GPC3 (Glypican 3)
4d
An early clinical study to evaluate the safety and clinical efficacy of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia (ChiCTR2500111445)
P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
New trial
|
CD19 (CD19 Molecule)
|
CD19 positive
4d
New P1 trial
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
DLL3 expression
11d
New trial
|
CD19 positive
13d
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=30, Recruiting, Beijing GoBroad Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
GPC3 (Glypican 3)
|
cyclophosphamide • fludarabine IV
13d
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC (clinicaltrials.gov)
P1, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
New P1 trial
20d
CARAML: Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Great Ormond Street Hospital for Children NHS Foundation Trust | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
Enrollment closed • Trial primary completion date
|
CD33 (CD33 Molecule)
|
BE CAR33 T
2ms
New P1 trial • First-in-human
2ms
New P1 trial
|
cyclophosphamide • fludarabine IV
2ms
New trial
2ms
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Beijing GoBroad Hospital
New P1 trial
|
cyclophosphamide • fludarabine IV